ThesisArvinas: the story is balanced — ARV-471 (breast cancer) Phase 3 trial enrollment updates and interim efficacy data - primary near-term catalyst
★ Analysts see FY2026 revenue reaching $296M — +12.8% growth in a single year.
What Moves the Stock
- 01ARV-471 (breast cancer) Phase 3 trial enrollment updates and interim efficacy data - primary near-term catalyst
- 02ARV-110 (prostate cancer) Phase 2 expansion data and potential Phase 3 initiation decisions
- 03New partnership announcements or expansion of existing collaborations (Pfizer, Bayer, Genentech)
- 04FDA regulatory interactions, breakthrough therapy designations, or accelerated approval pathway eligibility
- 05Cash runway updates and financing events - critical given negative $300M annual cash burn
- 06Collaboration revenue from partnerships (Pfizer, Bayer, Genentech) - estimated 70-80% of current revenue
- 07Research grants and milestone payments - estimated 20-30%
- 08No product sales yet - pre-commercial stage with anticipated first approval timeline 2027-2028
My Notes
- growth - High-risk, high-reward clinical-stage biotech attracts speculative growth investors betting on binary clinical outcomes.
- Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (product revenues not expected…
- Watch on earnings: ARV-471 Phase 3 trial enrollment completion and interim analysis timing announcements, ARV-110 objective response rates and duration of response in Phase 2 expansion cohorts, Cash and marketable securities balance relative to quarterly burn rate.
One Sentence Summary:
Arvinas: the story is balanced — arv-471 (breast cancer) phase 3 trial enrollment updates and interim efficacy data - primary near-term catalyst.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
